Data / Drug companies / Zydus Pharmaceuticals USA Inc.
Zydus Pharmaceuticals USA Inc.: 303 products in the FDA NDC directory, labeler code 68382
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Zydus Pharmaceuticals USA Inc. (labeler code 68382) lists 303 products in the FDA National Drug Code Directory, covering 97 finished drugs by generic name. By type: 303 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on May 21, 2026.
The request: Watch Zydus Pharmaceuticals USA Inc. (FDA labeler code 68382): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68382
- Products in commercial distribution
- 303
- Packages
- 1,174
- Finished drugs by generic name
- 97
- Prescription products
- 303
- Over the counter products
- 0
- Flagged as original packager
- 296 of 296 products that carry the flag
- Started marketing in the last 12 months
- 5
- Products with a marketing end date set
- 2
- Earliest marketing start
- October 8, 2005
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 303 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 303 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 110 | 36.3% |
| Tablet, film coated | 54 | 17.8% |
| Tablet, extended release | 34 | 11.2% |
| Capsule, extended release | 28 | 9.2% |
| Capsule | 19 | 6.3% |
| Tablet, coated | 8 | 2.6% |
| Tablet, film coated, extended release | 8 | 2.6% |
| Patch | 7 | 2.3% |
| Capsule, delayed release | 5 | 1.7% |
| Capsule, coated pellets | 5 | 1.7% |
| Tablet, orally disintegrating | 4 | 1.3% |
| Tablet, delayed release | 3 | 1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Verapamil hydrochloride | 68382-563 | Tablet | Generic drugs (ANDA) | May 21, 2026 |
| Verapamil hydrochloride | 68382-562 | Tablet | Generic drugs (ANDA) | May 21, 2026 |
| Verapamil hydrochloride | 68382-561 | Tablet | Generic drugs (ANDA) | May 21, 2026 |
| Trazodone Hydrochloride | 68382-610 | Tablet | Generic drugs (ANDA) | January 22, 2026 |
| Trazodone Hydrochloride | 68382-609 | Tablet | Generic drugs (ANDA) | January 22, 2026 |
| Gabapentin | 68382-357 | Tablet | Generic drugs (ANDA) | September 18, 2025 |
| Gabapentin | 68382-356 | Tablet | Generic drugs (ANDA) | September 18, 2025 |
| Gabapentin | 68382-355 | Tablet | Generic drugs (ANDA) | September 18, 2025 |
| Oxcarbazepine | 68382-693 | Tablet | Generic drugs (ANDA) | July 10, 2025 |
| Oxcarbazepine | 68382-692 | Tablet | Generic drugs (ANDA) | July 10, 2025 |
| Oxcarbazepine | 68382-691 | Tablet | Generic drugs (ANDA) | July 10, 2025 |
| Minocycline hydrochloride | 68382-550 | Tablet, extended release | Generic drugs (ANDA) | June 12, 2025 |
| Minocycline hydrochloride | 68382-534 | Tablet, extended release | Generic drugs (ANDA) | June 12, 2025 |
| Minocycline hydrochloride | 68382-532 | Tablet, extended release | Generic drugs (ANDA) | June 12, 2025 |
| Topiramate | 68382-498 | Capsule, coated pellets | Generic drugs (ANDA) | October 24, 2024 |
| Topiramate | 68382-864 | Capsule, extended release | Generic drugs (ANDA) | September 10, 2024 |
| Topiramate | 68382-863 | Capsule, extended release | Generic drugs (ANDA) | September 10, 2024 |
| Topiramate | 68382-769 | Capsule, extended release | Generic drugs (ANDA) | September 10, 2024 |
| Gabapentin | 68382-608 | Tablet | Generic drugs (ANDA) | January 25, 2024 |
| Gabapentin | 68382-607 | Tablet | Generic drugs (ANDA) | January 25, 2024 |
| Topiramate | 68382-358 | Capsule, extended release | Generic drugs (ANDA) | November 13, 2023 |
| Pitavastatin calcium | 68382-483 | Tablet | Generic drugs (ANDA) | November 2, 2023 |
| Pitavastatin calcium | 68382-482 | Tablet | Generic drugs (ANDA) | November 2, 2023 |
| Pitavastatin calcium | 68382-481 | Tablet | Generic drugs (ANDA) | November 2, 2023 |
| Estradiol | 68382-329 | Patch | Generic drugs (ANDA) | November 2, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.